PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of “Buy” by Brokerages

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) have been assigned an average recommendation of “Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $14.25.

Several equities research analysts recently commented on the company. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Thursday, August 1st. Finally, B. Riley reduced their target price on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, June 12th.

Institutional Trading of PDS Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDSB. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology during the second quarter worth approximately $115,000. Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology in the second quarter worth $120,000. Cubist Systematic Strategies LLC purchased a new position in shares of PDS Biotechnology in the second quarter worth about $146,000. Blair William & Co. IL increased its stake in shares of PDS Biotechnology by 204.4% in the second quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares during the period. Finally, Ground Swell Capital LLC purchased a new stake in shares of PDS Biotechnology in the second quarter worth about $67,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Stock Performance

PDS Biotechnology stock opened at $3.00 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a market cap of $110.04 million, a P/E ratio of -2.21 and a beta of 1.88. The firm has a 50-day moving average of $3.39 and a 200-day moving average of $3.58. PDS Biotechnology has a 1-year low of $2.53 and a 1-year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.08. During the same period in the previous year, the firm earned ($0.37) earnings per share. Sell-side analysts expect that PDS Biotechnology will post -1.3 EPS for the current year.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.